<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIPTORELIN PAMOATE</span><br/>(trip-tor'e-lyn)<br/><span class="topboxtradename">Trelstar Depot<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">gonadotropin-releasing hormone analog</span><br/><b>Prototype: </b>Leuprolide Acetate<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3.75 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic luteinizing releasing hormone agonist (LHRH or GnRH) with greater potency than naturally occurring luteinizing hormone.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Potent inhibitor of gonadotropin secretion. In men, the level of serum testosterone is equivalent to a surgically castrated
         man.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative treatment of advanced prostate cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to triptorelin, other LHRH agonists, or LHRH; pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Prostatic carcinoma; patients with impending spinal cord compression or severe urogenital disorder; premenstrual syndrome;
         renal insufficiency.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prostate Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 3.75 mg q mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give deep into a large muscle.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Hot flushes,</span> pain, leg pain, fatigue. <span class="typehead">CV:</span> Hypertension. <span class="typehead">GI:</span> Diarrhea, vomiting. <span class="typehead">Hematologic:</span> Anemia. <span class="typehead">Musculoskeletal:</span> Skeletal pain. <span class="typehead">CNS:</span> Headache, dizziness, insomnia, impotence, emotional lability. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Urogenital:</span> Urinary retention, UTI. <span class="typehead">Other:</span> Pain at injection site. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May interfere with tests for <span class="alt">pituitary-gonadal function.</span>
</p>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 13 h. <span class="typehead">Duration:</span> 1 mo. <span class="typehead">Metabolism:</span> Unknown. <span class="typehead">Elimination:</span> Eliminated by liver and kidneys. <span class="typehead">Half-Life:</span> 3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of disease flare, especially during the first 12 wk of therapy: Increased bone pain, blood in urine,
            urinary obstruction, or symptoms of spinal compression.
         </li>
<li>Lab tests: Periodic serum testosterone, PSA, acid phosphatase levels; urinary and serum calcium; urinary calcium/creatinine
            ratio; lipid profile in those at risk for atherosclerosis.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Disease flare (see <small>ASSESSMENT &amp; DRUG EFFECTS</small>) is a common, temporary adverse effect of therapy; however, symptoms may become serious enough to report to the physician.
         </li>
<li>Notify physician promptly of the following: S&amp;S of an allergic reaction (itching, hives, swelling of face, arms, or legs;
            tingling in mouth or throat, tightness in chest or trouble breathing); weakness or loss of muscle control; rapid weight gain.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>